Nav: Home

Increase in lifestyle-related cancers over past decade spotlights need for prevention

June 02, 2018

SEATTLE - Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

"While the increase in lung, colorectal, and skin cancers over the past decade is concerning, the prevention potential is substantial," said Dr. Christina Fitzmaurice, Assistant Professor of Global Health at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, whose organization coordinated the study. "Vital prevention efforts such as tobacco control, dietary interventions, and broader health promotion campaigns need to be scaled up in response to this rise in lifestyle-related cancers."

The study, published today in JAMA Oncology, covers 1990 to 2016; it is part of the Global Burden of Disease (GBD) study, a comprehensive effort to quantify health internationally. Researchers reviewed 29 cancer groups, including lung, breast, prostate, skin, colorectal, pancreatic, stomach, and liver cancers, as well as leukemia and other cancer groups (full list below). The study provides findings by age and sex for 195 countries and territories.

While lifestyle-related cancers saw a universal increase from 2006 to 2016, several cancers from infectious causes - including cervical and stomach cancers - decreased over the same time period.

Study estimates were analyzed using a Socio-demographic Index (SDI) based on rates of education, fertility, and income. SDI is more comprehensive than the historical "developed" versus "developing" nations framework. Countries with high SDI have high levels of income and education and low fertility, whereas low-SDI countries have low levels of income and education and high fertility.

Large disparities in cancer incidence and death persist between high- and low-SDI countries. Researchers found rates of cancer incidence and death remained higher in high-SDI countries in 2016. For example, the odds of developing breast cancer over the course of one's lifetime were the highest - at 1 in 10 women - in high-SDI countries, but only 1 in 50 for women in low-SDI countries.

Conversely, the largest and fastest increase in new cancer cases between 2006 and 2016 occurred in middle-SDI countries. And women in low-SDI countries are nearly four times more likely to develop cervical cancer than women in high-SDI countries, and in 2016, cervical cancer was the most common cause of cancer incidence and death in low-SDI countries.

"Ensuring universal access to health care is a vital prerequisite for early detection and cancer treatment," said Fitzmaurice. "And improving access to advanced diagnostic technologies not commonly available in low-SDI countries is a critical step toward achieving health equity globally."

Additional key findings include:
  • In 2016, there were 17.2 million cancer cases worldwide, an increase of 28% over the past decade. There were 8.9 million cancer deaths the same year.
  • While cancer death rates decreased in a majority of countries from 2006 to 2016, incidence rates conversely increased.
  • Breast cancer was the leading cause of cancer death in women.
  • Lung cancer was the leading cause of cancer death in men; it was also the leading cause of cancer mortality globally, accounting for nearly 20 percent of all cancer deaths in 2016.
  • Prostate cancer is one of the most common causes of cancer incidence and death in men, in both high- and low-SDI countries, but especially in sub-Saharan Africa.
"Worst" and "best" countries and global

  1. Tracheal, bronchus, and lung cancer: North Korea (56.9), Kenya (4.2), global (30.2)
  2. Colon and rectum cancer: Netherlands (57.5), The Gambia (4.3), global (25.9)
  3. Breast cancer: Luxembourg (61.8), Niger (5.8), global (24.1)
  4. Non-melanoma skin cancer: Australia (300.4), Bangladesh (0.7), global (23.2)
  5. Prostate cancer: Dominica (113.1), North Korea (2.4), global (22.1)
  6. Stomach cancer: South Korea (44.5), Namibia (2.7), global (17.3)
  7. Liver cancer: Mongolia (108.4), Morocco (1.9), global (14.6)
  8. Other neoplasms: Malawi (39.6), Syria (2.6), global (10.9)
  9. Cervical cancer: Somalia (34.0), Qatar (1.1), global (7.0)
  10. Leukemia: New Zealand (20.3), Zambia (2.0), global (6.8)
  11. Non-Hodgkin lymphoma: Canada (21.2), Kyrgyzstan (1.5), global (6.7)
  12. Bladder cancer: Lebanon (31.1), Nigeria (1.2), global (6.7)
  13. Esophageal cancer: Malawi (25.2), Syria (0.7), global (6.6)
  14. Pancreatic cancer: Czech Republic (12.5), India (2.6), global (6.4)
  15. Uterine cancer: Latvia (23.1), Bangladesh (0.8), global (6.0)
  16. Lip and oral cavity cancer: Pakistan (22.1), Sao Tome and Principe (1.0), global (5.5)
  17. Kidney cancer: Latvia (20.5), Nepal (1.0), global (5.0)
  18. Brain and nervous system cancer: Iceland (20.8), Namibia (1.4), global (4.6)
  19. Malignant skin melanoma: Australia (55.6), Nepal (0.2), global (4.1)
  20. Ovarian cancer: Estonia (9.3), Niger (1.2), global (3.6)
  21. Thyroid cancer: Iceland (18.7), Ghana (0.2), global (3.3)
  22. Gallbladder and biliary tract cancer: Chile (11.5), Uzbekistan (0.6), global (2.8)
  23. Larynx cancer: Cuba (8.8), The Gambia (0.6), global (2.7)
  24. Other pharynx cancer: Hungary (7.3), Palestine (0.2), global (2.4)
  25. Multiple myeloma: Barbados (6.3), Tajikistan (0.4), global (2.1)
  26. Nasopharynx cancer: Malaysia (5.1), Mali (0.1), global (1.3)
  27. Hodgkin lymphoma: Greece (5.3), Syria (0.1), global (1.0)
  28. Testicular cancer: Chile (6.4), Mozambique (0.04), global (0.9)
  29. Mesothelioma: United Kingdom (2.9), Palestine (0.1), global (0.5)

"Worst," and "best" countries and global

  1. Tracheal, bronchus, and lung cancer: North Korea (61.7), Egypt (4.8), global (25.8)
  2. Colon and rectum cancer: Hungary (31.3), Sri Lanka (5.0), global (12.8)
  3. Stomach cancer: Mongolia (44.0), Maldives (3.2), global (12.6)
  4. Liver cancer: Mongolia (114.7), Morocco (2.0), global (12.1)
  5. Breast cancer: Tonga (24.7), Oman (4.0), global (7.9)
  6. Other neoplasms: Malawi (37.6), Syria (2.6), global (6.4)
  7. Esophageal cancer: Malawi (32.4), Syria (0.8), global (6.2)
  8. Pancreatic cancer: Uruguay (12.8), Bangladesh (2.5), global (6.2)
  9. Prostate cancer: Dominica (54.9), North Korea (1.9), global (6.1)
  10. Leukemia: Syria (15.3), Bangladesh (1.9), global (4.6)
  11. Non-Hodgkin lymphoma: Grenada (11.0), Kyrgyzstan (1.4), global (3.6)
  12. Cervical cancer: Zimbabwe (28.7), Syria (0.6), global (3.5)
  13. Brain and nervous system cancer: Palestine (8.3), Japan (1.2), global (3.2)
  14. Bladder cancer: Malawi (11.8), Albania (0.9), global (2.9)
  15. Lip oral cavity cancer: Kiribati (14.6), Syria (0.6), global (2.6)
  16. Gallbladder and biliary tract cancer: Chile (11.3), Uzbekistan (0.6), global (2.5)
  17. Ovarian cancer: Lithuania (5.9), United Arab Emirates (0.9), global (2.4)
  18. Kidney cancer: Czech Republic (7.1), Bangladesh (0.5), global (2.0)
  19. Other pharynx cancer: India (6.1), Syria (0.2), global (1.7)
  20. Larynx cancer: Cuba (5.3), Japan (0.4), global (1.6)
  21. Multiple myeloma: Dominica (5.9), Tajikistan (0.4), global (1.5)
  22. Uterine cancer: Grenada (5.4), Maldives (0.5), global (1.3)
  23. Malignant skin melanoma: New Zealand (6.6), Bangladesh (0.2), global (0.9)
  24. Nasopharynx cancer: Malaysia (3.7), Chile (0.1), global (0.9)
  25. Non-melanoma skin cancer: Zimbabwe (4.5), Bangladesh (0.2) global (0.8)
  26. Thyroid cancer: Zimbabwe (2.3), Syria (0.2), global (0.6)
  27. Mesothelioma: United Kingdom (2.6), Palestine (0.1), global (0.5)
  28. Hodgkin lymphoma: Afghanistan (2.2), Japan (0.1), global (0.4)
  29. Testicular cancer: Kiribati (1.0), Maldives (0.02), global (0.1)


Highest rates

  1. Australia (743.8)
  2. New Zealand (542.8)
  3. United States (532.9)
  4. Netherlands (477.3)
  5. Luxembourg (455.4)
  6. Iceland (455.0)
  7. Norway (446.1)
  8. United Kingdom (438.6)
  9. Ireland (429.7)
  10. Denmark (421.7)

Lowest rates

  1. Syria (85.0)
  2. Bhutan (86.0)
  3. Algeria (86.7)
  4. Nepal (90.7)
  5. Oman (94.9)
  6. Maldives (101.3)
  7. Sri Lanka (101.6)
  8. Niger (102.3)
  9. Timor-Leste (105.9)
  10. India (106.6)


Highest rates

  1. Mongolia (272.1)
  2. Zimbabwe (245.8)
  3. Dominica (203.1)
  4. Hungary (202.7)
  5. Grenada (201.0)
  6. Uruguay (190.6)
  7. Tonga (189.7)
  8. North Korea (188.7)
  9. Saint Vincent and the Grenadines (183.1)
  10. Croatia (180.2)

Lowest rates

  1. Syria (67.4)
  2. Algeria (67.5)
  3. Oman (69.2)
  4. Maldives (72.0)
  5. Sri Lanka (74.7)
  6. Bhutan (78.6)
  7. Uzbekistan (80.6)
  8. Nicaragua (80.9)
  9. Morocco (81.0)
  10. Qatar (81.6)
The study, "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016," was published today in JAMA Oncology.

Media contacts:

IHME: Kelly Bienhoff, +1-206-897-2884 (office); +1-913-302-3817 (mobile);

IHME: Dean Owen, +1-206-897-2858 (office); +1-206-434-5630 (mobile);

JAMA Network Media Relations, +1-312-464-JAMA (5262);

About the Institute for Health Metrics and Evaluation

The Institute for Health Metrics and Evaluation (IHME) is an independent global health research organization at the University of Washington that provides rigorous and comparable measurement of the world's most important health problems and evaluates the strategies used to address them. IHME makes this information widely available so that policymakers have the evidence they need to make informed decisions about how to allocate resources to improve population health.

Institute for Health Metrics and Evaluation

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".